BeStock  
Stocks › Biotechnology › DFTX

Definium Therapeutics DFTX

US equityMarket cap rank #2233Biotechnology
$28.34 −$1.14 (-3.87%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $28.05 -1.02%
Open$29.14
Prev close$29.48
Day range$28.18 – $29.51
Volume3.24M
Market cap$3.88B
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$0.00
Operating profit-$72.28M-58.3% YoY
Net profit-$50.96M+24.2% YoY
Diluted EPS-$0.46+41.0% YoY
Free cash flow-$52.98M-79.2% YoY
Operating cash flow-$52.98M

Revenue, last 8 quarters

$0.0Dec '24$0.0Mar '25$0.0Jun '25$0.0Sep '25$0.0Dec '25$0.0Mar '26$0.0Jun '26$0.0Sep '26

Net profit, last 8 quarters

$-34.7MDec '24$-23.3MMar '25$-42.7MJun '25$-67.3MSep '25$-50.4MDec '25$-77.1MMar '26$-159.0MJun '26$-51.0MSep '26

Diluted EPS by quarter

-0.41Dec '24-0.35Mar '25-0.50Jun '25-0.78Sep '25-0.50Dec '25-0.71Mar '26-1.44Jun '26-0.46Sep '26

Free cash flow by quarter

$-25.4MDec '24$-29.4MMar '25$-29.6MJun '25$-29.6MSep '25$-43.0MDec '25$-42.6MMar '26$-52.8MJun '26$-53.0MSep '26

Annual revenue

$0.0FY20$0.0FY21$0.0FY22$0.0FY23$0.0FY24$0.0FY25

Profitability & balance sheet

Return on equity-61.4%
Return on assets-51.5%
Return on invested capital-60.1%
Current ratio15.53
Liabilities / assets9.9%
Cash & investments$1.05B
Total debt$36.66M
Net cash (debt)$1.01B

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Operating Revenue $0.00 $0.00 $0.00 $0.00 $0.00
Operating Expense $72.28M $75.08M $59.22M $166.31M $47.58M
Selling and Admin Expenses $26.14M $26.41M $17.74M $48.64M $14.06M
-General & Admin Expense $26.14M $26.41M $17.74M $48.64M $14.06M
Research & Development $46.14M $48.67M $41.48M $117.67M $33.52M
Operating Profit -$72.28M -$75.08M -$59.22M -$166.31M -$47.58M
Net Non-Operating Interest Income (Expense) $8.99M $2.35M $2.21M $5.48M $2.22M
Non-Operating Interest Income $10.14M $3.59M $3.46M $10.96M $3.49M
Non-Operating Interest Expense $1.15M $1.23M $1.25M $5.48M $1.27M
Other Income (Expense) $12.33M -$86.26M -$20.09M -$22.96M -$5.08M
Gain on Sale of Security $12.33M -$86.26M -$20.09M -$22.96M -$5.08M
Pretax Profit -$50.96M -$158.99M -$77.10M -$183.79M -$50.44M
Net Profit -$50.96M -$158.99M -$77.10M -$183.79M -$50.44M
Profit from Continuing Operations -$50.96M -$158.99M -$77.10M -$183.79M -$50.44M
Net Income to Parent Company -$50.96M -$158.99M -$77.10M -$183.79M -$50.44M
Net Income to Common Stockholders -$50.96M -$158.99M -$77.10M -$183.79M -$50.44M
Basic EPS -$0.37 -$1.44 -$0.71 -$2.06 -$0.50
Diluted EPS -$0.46 -$1.44 -$0.71 -$2.06 -$0.50
Special Income (Charges) – – – $0.00 $0.00

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $1.07B $1.11B $401.29M $440.10M $440.10M
Total Current Assets $1.05B $1.09B $380.56M $419.32M $419.32M
Cash and Cash Equivalents & Short-Term Investments $1.05B $1.08B $373.42M $411.59M $411.59M
-Cash and Cash Equivalents $241.15M $655.27M $262.52M $257.84M $257.84M
-Short Term Investments $805.70M $428.61M $110.90M $153.76M $153.76M
Other Current Assets $4.91M $8.22M $7.14M $7.73M $7.73M
Total Non-Current Assets $22.52M $20.80M $20.73M $20.78M $20.78M
Goodwill and Other Intangible Assets $19.92M $19.92M $19.92M $19.92M $19.92M
-Goodwill $19.92M $19.92M $19.92M $19.92M $19.92M
Other Non-Current Assets $2.61M $880,000.00 $812,000.00 $862,000.00 $862,000.00
Total Liabilities $106.25M $194.22M $122.44M $107.77M $107.77M
Total Current Liabilities $67.73M $157.20M $81.11M $66.70M $66.70M
Payables $9.28M $6.97M $7.13M $5.35M $5.35M
-Accounts Payable $9.28M $6.97M $7.13M $5.35M $5.35M
Current Accrued Expenses $18.48M $17.12M $17.10M $10.98M $10.98M
Other Current Liabilities $21.33M $113.02M $49.47M $40.91M $40.91M
Total Non-Current Liabilities $38.52M $37.02M $41.33M $41.08M $41.08M
Long Term Debt and Capital Lease Obligation $36.66M $36.47M $40.77M $40.58M $40.58M
-Long Term Debt $36.66M $36.47M $40.77M $40.58M $40.58M
Other Non-Current Liabilities $1.86M $549,000.00 $559,000.00 $496,000.00 $496,000.00
Total Equity $968.03M $918.68M $278.85M $332.33M $332.33M
Stockholders' Equity $968.03M $918.68M $278.85M $332.33M $332.33M
Capital Stock $0.00 $0.00 $0.00 $0.00 $0.00
-Common Stock $0.00 $0.00 $0.00 $0.00 $0.00
Additional Paid-In Capital $1.84B $1.74B $937.80M $913.91M $913.91M
Retained Earnings -$869.72M -$818.76M -$659.77M -$582.67M -$582.67M
Gains/Losses Not Affecting Retained Earnings -$829,000.00 $417,000.00 $824,000.00 $1.09M $1.09M

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow -$52.98M -$52.78M -$42.63M -$131.56M -$42.98M
Net cash flow from continuing operations -$52.98M -$52.78M -$42.63M -$131.56M -$42.98M
Net Income from Continuing Operations -$50.96M -$158.99M -$77.10M -$183.79M -$50.44M
Gain/Loss from Continuing Operations -$12.34M $86.22M $20.05M $22.83M $5.06M
Other Non-Cash Items -$363,000.00 $4.66M $1.25M $1.69M $632,000.00
Change in Working Capital $2.92M $6.28M $5.45M $9.44M -$2.29M
-Change in Prepaid Assets $2.49M -$264,000.00 $585,000.00 $152,000.00 -$2.44M
-Change in Payables and Accrued Expense $3.81M $6.69M $4.77M $9.30M -$1.84M
-Change in Other Current Assets -$21,000.00 -$133,000.00 $118,000.00 $30,000.00 $17,000.00
-Change in Other Current Liabilities -$59,000.00 -$10,000.00 -$29,000.00 -$40,000.00 -$23,000.00
Net cash flow from investing -$372.80M -$316.74M $42.00M -$151.61M $34.98M
Net Cash Flow from Continuing Investing Activities -$372.80M -$316.74M $42.00M -$151.61M $34.98M
Net Investment Purchase and Sale -$372.80M -$316.74M $42.00M -$151.61M $34.98M
Financing Cash Flow $11.66M $762.27M $5.31M $267.27M $245.87M
Net Cash Flow from Continuing Financing Activities $11.66M $762.27M $5.31M $267.27M $245.87M
Net Issuance Payments Of Debt $0.00 – – $20.00M $0.00
Net Common Stock Issuance $0.00 $804.72M $276,000.00 $258.86M $258.86M
Proceeds from Stock Option Exercised $18.17M -$2.69M $5.03M $1.04M -$811,000.00
Net Other Financing Charges -$6.50M – – -$12.63M -$12.18M
Ending Cash Balance $241.15M $655.27M $262.52M $257.84M $257.84M
Net Change in Cash -$414.11M $392.75M $4.68M -$15.90M $237.88M
Beginning Cash Balance $655.27M $262.52M $257.84M $273.74M $19.96M
Effect of Exchange Rate Changes -$5,000.00 -$1,000.00 $3,000.00 -$7,000.00 $1,000.00
Free Cash Flow -$52.98M -$52.78M -$42.63M -$131.56M -$42.98M
Depreciation & Depletion & Amortization – – – $0.00 $0.00

Discussion

No comments yet — be the first to weigh in on DFTX.

Sign in to join the discussion.

Scroll to Top